Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025Neuro-OncologyOpen Access

CTP-14. Treatment with MEK inhibitors in patients with low-grade gliomas in Neurofibromatosis type 1: a preliminary report

View Full Paper
Ask AI
Bookmark
Share

Authors

CFCarla FonteMNMarco Di NicolaMGMilena Guidi

Discussion

Loading...

Member takes

Overview

Preliminary report shows MEK inhibitors improve symptoms in children with low-grade gliomas and NF1, suggesting effective treatment options.

Key Points

  • This research aims to evaluate the efficacy and safety of MEK inhibitors in pediatric low-grade gliomas associated with Neurofibromatosis type 1.
  • Evaluated MEK inhibitors in 6 patients with NF1-related pLGGs
  • Administered selumetinib and trametinib after previous treatment failure
  • Monitored radiological response via MRI assessments every 3-6 months
  • At initial evaluation, 83.3% of patients showed a partial response with an average volume reduction of 57.4%
  • 1 patient had stable disease; best response noted at a mean of 5.6 months
  • At least 4 patients experienced clinical benefits, including improvements in visual field and vigilance

Cite This Study

Fonte et al. (2025) studied this question.

synapsesocial.com/papers/69254366c0ce034ddc358510https://doi.org/10.1093/neuonc/noaf201.0586
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selumetinib as a Target Therapy in Progressive Paediatric Low‐Grade Gliomas—Case Series ( <scp>pLGG</scp> )2026
  2. 2LGG-39. REAL-LIFE STUDY OF THE EFFICACY AND TOLERANCE OF TRAMETINIB IN THE TREATMENT OF LOW-GRADE GLIOMAS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 12024
  3. 3LMIC-27. MEK INHIBITORS IN PEDIATRIC LOW-GRADE GLIOMAS (PLGG)- EARLY EXPERIENCE IN A RESOURCE LIMITED SETTING2024 · 5 citations
  4. 4Durable response to trametinib in a neurofibromatosis type 1 associated adult glioma—a case report2026
  5. 5Neurofibromatosis Type 1 and MEK Inhibition: A Comprehensive Review with Focus on Selumetinib Therapy2025 · 5 citations